Stephens resumed coverage of Cryoport (CYRX) with an Overweight rating and $13 price target The firm says the company has a large platform of supply chain solutions for the growing cell and gene therapy industry. Cryoport will benefit as the macro environment normalizes and therapies move through the clinical pipeline, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX: